Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 37 (5) , 856-864
Abstract
In postmenopausal women with osteoporosis, denosumab (DMAb) therapy through 10 years resulted in significantly higher degree of mineralization of bone, with a subsequent increase from years 2–3 to year 5 and no further difference between years 5 and 10. Our aim was to assess the variables reflecting the quality of bone mineral and organic matrix (Fourier transform infrared microspectroscopy), and the microhardness of bone (Vickers microindentation). Cross-sectional assessments were performed in blinded fashion on iliac bone biopsies from osteoporotic women (72 from FREEDOM trial, 49 from FREEDOM Extension trial), separately in cortical and cancellous compartments. After 2–3 years of DMAb, mineral/matrix ratio and microhardness of cortical bone were significantly higher compared with placebo, whereas mineral maturity, mineral crystallinity, mineral carbonation, and collagen maturity were not different in both bone compartments. Through 5 years of DMAb, mineral carbonation was significantly lower and mineral/matrix ratio, mineral maturity, and crystallinity were significantly higher versus 2–3 years and were not different between 5 and 10 years, with the exception of mineral maturity in cancellous bone. These data support a transition of mineral to more mature crystals (within physiological range) and the completeness of secondary mineralization within 5 years of DMAb treatment. Microhardness in cortical and cancellous compartments was significantly lower at 5 years of DMAb versus 2–3 years and was not different from years 5 to 10. The lower microhardness at years 5 and 10 is likely the result of maturation of the organic matrix in a persistently low state of bone remodeling over 5 and 10 years. © 2022 American Society for Bone and Mineral Research (ASBMR).Keywords
Funding Information
- Amgen Inc.
- Amgen
This publication has 21 references indexed in Scilit:
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumabNature Reviews Drug Discovery, 2012
- The Ratio 1660/1690 cm−1 Measured by Infrared Microspectroscopy Is Not Specific of Enzymatic Collagen Cross-Links in Bone TissuePLOS ONE, 2011
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- Respective roles of organic and mineral components of human cortical bone matrix in micromechanical behavior: An instrumented indentation studyJournal of the Mechanical Behavior of Biomedical Materials, 2011
- Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibodyBone, 2011
- Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studiesJournal of Bone and Mineral Research, 2010
- Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewesBone, 2010
- Mineral maturity and crystallinity index are distinct characteristics of bone mineralJournal of Bone and Mineral Metabolism, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patientsBone, 2008